Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
OSI Pharmaceuticals |
---|---|
Information provided by: | OSI Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00116909 |
Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy
Condition | Intervention | Phase |
---|---|---|
Locally Recurrent or Metastatic Cancer of the Head and Neck Must Have Failed First-Line Therapy |
Drug: OSI 7904L |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Histologically or cytologically confirmed metastatic or locally recurrent SCCHN that is incurable with surgery or radiation therapy ECOG performance status 0-2 No more tha 1 prior chemotharapy regimen for metastatic or locally recurrent disease Adequate bone marrow, Hepatic and renal function. At least one target lesion greater than or equal to 20 mm.
Exclusion Criteria:
Symptomatic brain metasteses which are not stable, are not adequately controlled, are potenially life threatening or required radiation in the last 28 days Pregnant or lactating women. Concurrent anticancer therapy or other investigational drugs Patients with active or uncontrolled infections or other serious illnesses or medical conditions.
United States, Massachusetts | |
Dana-Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
United States, New York | |
Stony Brook University Hospital | |
Stony Brook, New York, United States, 11794 | |
United States, Tennessee | |
Sarah Cannon Cancer Center | |
Nashville, Tennessee, United States, 37203 | |
The Vanderbilt Cancer Center | |
Nashville, Tennessee, United States, 37232 |
Study ID Numbers: | OSI-904-203 |
Study First Received: | June 30, 2005 |
Last Updated: | March 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00116909 |
Health Authority: | United States: Food and Drug Administration |
Epidermoid carcinoma Squamous cell carcinoma Head and Neck Neoplasms Carcinoma, squamous cell Neoplasm Metastasis |
Carcinoma, Squamous Cell Carcinoma, squamous cell of head and neck Recurrence Carcinoma |
Neoplastic Processes Neoplasms Pathologic Processes Neoplasms by Site |